60 Degrees Pharma Secures Exclusive Option for Castanospermine in Tick-Borne Diseases
SXTP sits 23% above its 52-week low of $1.22 on light trading volume (0.4× avg).
Summary
60 Degrees Pharmaceuticals entered an exclusive option agreement with Florida State University to advance castanospermine for the therapeutic treatment of multiple tick-borne diseases. This agreement provides an evaluation period to develop a commercialization strategy for the compound, which is derived from Australian Chestnut. This follows a prior license for Australian Chestnut Extract and indicates a strategic shift to prioritize drug development over dietary supplements. For a micro-cap company facing significant financial challenges, including a critical cash runway and proposed dilutive reverse stock split, expanding its drug pipeline into new therapeutic areas represents a potential long-term value driver.
At the time of this announcement, SXTP was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.22 to $10.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.